What does it do?
OptiBiotix Health PLC (LON:OPTI) has developed technologies that modulate the human microbiome – the collective genome of the microbes in the body. It has done so by creating microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.
With an established pipeline of microbiome modulators, the firm is working on the prevention and management of chronic lifestyle diseases such as obesity, hypercholesterolemia and lipid profiles and diabetes.
Its product roster includes weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).
How’s it doing?
In a comprehensive update on trading released on January 17, Optibiotix said total sales for the 12 months ended November 30 were £808,000. Adding in £617,000 from the disposal of a small tranche of shares it owns in sister company SkinBioTherapeutics, total income was £1.43mln, up from £541,614 a year earlier.
In terms of funding, the firm had just over £1.2mln in cash and trade debtors at the year-end, or £1.4mln once R&D tax credits are recovered. It also has a £7mln stake in SkinBioTherapeutics, which would support what it termed “capital growth”.
- On 6 April, OptiBiotix signed a contract manufacturing agreement with French food supplements and nutrition group, Laboratoire PYC, for the exclusive rights to manufacture meal replacement shakes for the UK firm’s GoFigure weight management range
- In early April, the firm signed a contract manufacturing deal with a Danish company called Fipros for its to manufacture the weight management product SlimBiome under licence
- In late March, the company signed an exclusive licence agreement for its OptiBiome weight loss ingredient with Australian firm OptiPharm Pty Ltd